(Q36658960)

15 August 2017

1 reference

title

Update on osteoporosis therapy (English)

1 reference

15 August 2017

0 references

2

John P Bilezikian

1 reference

15 August 2017

author name string

João Lindolfo C Borges

series ordinal

1

1 reference

15 August 2017

publication date

1 August 2006

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

15 August 2017

published in

1 reference

15 August 2017

volume

50

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

755-763

1 reference

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

High-intensity strength training in nonagenarians. Effects on skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Preventing osteoporosis-related fractures: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Bone density changes with once weekly risedronate in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Response of bone mineral density to once-weekly administration of risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

Inhibition of osteoclast recruitment at a local site by 1-hydroxyethylidene-1,1-bisphosphonate (HEBP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400020

10.1590/S0004-27302006000400020

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference